<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198002</url>
  </required_header>
  <id_info>
    <org_study_id>11352</org_study_id>
    <secondary_id>H9B-MC-BCDM</secondary_id>
    <secondary_id>CTRI/2011/07/001870</secondary_id>
    <nct_id>NCT01198002</nct_id>
  </id_info>
  <brief_title>A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate</brief_title>
  <acronym>FLEX M</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate Therapy (FLEX M)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to help answer if LY2127399 is safe and effective in the
      treatment of rheumatoid arthritis while on a background treatment of methotrexate.

      This study is comprised of 3 periods:

      Period 1: 52-week blinded treatment

      Period 2: additional 48-week unblinded treatment

      Period 3: 48-week post-treatment follow-up
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated not based on safety concerns, but due to insufficient efficacy.
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology 20% Response (ACR20) at Week 24</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response=(number of ACR20 responders) / (number of participants treated) * 100. All NR at Week 16 as well as all participants who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 52 in Van Der Heijde Modified Total Sharp Score (mTSS)</measure>
    <time_frame>Baseline, 52 Weeks</time_frame>
    <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range = 0 to 220 for 44 joints) and narrowing scores (range = 0 to 168 for 42 joints) were added to obtain the mTSS (range = 0 [normal] to 388 [maximal disease]). Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment and region as fixed factors and baseline as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response</measure>
    <time_frame>Baseline through 24 weeks and 52 weeks</time_frame>
    <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of RA. ACR50 Responder: had ≥50% improvement from baseline in both 68 tender joint (TJ) and 66 swollen joint (SJ) counts and ≥50% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response=(number (No.) of ACR50 responders) / (No. of Pts treated) * 100. ACR70 Responder: had ≥70% improvement from baseline in both TJ and SJ counts and ≥70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response= (No. of ACR70 responders) / (No. of Pts treated) * 100. All NR at Week 16 as well as all Pts who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Weeks 24 and 52 endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Based on 28 Joint Count and C-Reactive Protein Level (DAS28-CRP)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and participant's global assessment of disease activity using visual analog scale (VAS) (participant global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With DAS28-CRP Based European League Against Rheumatism (EULAR) Response</measure>
    <time_frame>Baseline through 24 weeks and 52 weeks</time_frame>
    <description>EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or NR based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: &gt;5.1 or &lt;0.6 improvement from baseline). Percentage of participants with DAS28-CRP based EULAR response =(number of participants with specific response) / (number of participants analyzed in the group) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Domain Scores and Summary Scores</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (CS), physical CS (PCS) and mental CS (MCS). Domain scores were calculated by summing each item for each domain and transforming scores into a 0-100 scale. Higher scores indicated better health status. If &lt; 50% of the questions within a domain were answered, raw scores were not calculated. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100. Higher score indicated better mental or physical health. LS means were calculated using ANCOVA with treatment, region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Fatigue Inventory (BFI) Individual Items and Impact Score</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>The BFI is a brief participant-reported questionnaire for the rapid assessment of fatigue severity and the impact of fatigue on daily functioning in the past 24 hours. The BFI contains 10 items; however, Item 1 is not included in the scoring of the scale as it asks about usual fatigue over the past week with the participant answering 'yes' or 'no'. The remaining 9 items assess fatigue severity (3 items) and impact of fatigue on daily functioning (6 items) using an 11-point numeric scale, with 0=no fatigue and 10=fatigue as bad as you can imagine. The fatigue impact subscale score is the average of the non-missing responses to 6 items: general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. If more than 3 items within the fatigue impact subscale were not answered by a participant, the subscale is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duration of Morning Stiffness (Minutes)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>The Investigator asks participants about the duration of their morning stiffness (in minutes) in and around the joints and records the duration. The Investigator should ask the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration is longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory Short Form (BPI-SF) Individual Items and Interference Scores</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>The BPI-SF is a self-reported scale that measures the severity of pain based on the worst pain, least pain, average pain experienced during the past 24-hours and pain based on the pain right now with scores ranging from 0 (no pain) to 10 (pain as severe as you can imagine). Pain interference score is the average of the responses in past 24-hours to 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life [each item scored from 0 (does not interfere) to 10 (completely interferes)]. If more than 3 items of the Pain Interference Score are not answered by a participant, the score were set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Clinical Response (MCR) During 52 Weeks</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change From Baseline in mTSS Less Than or Equal to (≤) 0</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range = 0 [normal] to 388 [maximal disease]). Percentage of participants = (number of participants with mTSS ≤0 at Week 24) / (total number of participants analyzed in the group) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in B Cell Subset Counts</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>B cell subset counts are: cluster designation (CD)19+ B cell counts, Immature/transitional [CD19+immunoglobulin D (IgD)-CD27-], Mature naïve (CD19+IgD+CD27-), Non-switched memory (CD19+IgD+CD27+) and Memory (CD19+IgD-CD27+). A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (PK): Constant Clearance</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Population estimate of constant clearance as determined by population PK analysis. A 2-compartment model was used in PK modeling. Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-LY2127399 Antibodies</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Participants with treatment-emergent anti-drug antibodies (ADA) were participants who had any sample from baseline up to and through Week 24 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). Percentage of participants with ADA=(number of participants with treatment-emergent ADA) / (number of participants assessed) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Structural Progression at Week 52</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>No structural progression is defined as the change in mTSS from baseline ≤0. The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). Percentage of participants=(number of participants with mTSS ≤0 at Week 52) / (total number of participants analyzed in the group) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in mTSS</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Immunoglobulin (Ig) Levels</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Immunoglobulins (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in Ig levels. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Joint Space Narrowing Score and Bone Erosions Score (Components of mTSS)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Percent Improvement (ACR-N)</measure>
    <time_frame>Baseline through 24 weeks and 52 weeks</time_frame>
    <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of either a) % change in TJ count, b) % change in SJ count, or c) the median % change of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater % improvement) and negative scores indicate a decline. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline DAS28-CRP as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Count (68 Joint Count)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Count (66 Joint Count)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Assessment of Pain [Visual Analog Scale (VAS)]</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>Participant's assessment of their current arthritis pain using VAS ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant's Global Assessment of Disease Activity (VAS)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>Participant's assessment of their current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity (VAS)</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>Physician's assessment of the participant's current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in HAQ-DI</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Absolute B Cell Counts</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ACR20 at Week 52</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, HAQ-DI (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of participants achieving ACR20 response=(number of ACR20 responders) /( number of participants treated) * 100. All NR at Week 16 as well as all participants who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Week 52 endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ACR20 Response</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, HAQ-DI (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and CRP. The Kaplan-Meier was used to estimate time to ACR20 response over the Treatment Period (52 weeks). Time to ACR20 response = (Date of the first post-baseline visit during the Treatment Period meeting ACR20 response criteria - Date of first injection of study treatment + 1) / 7. Week 16 NR are counted as responders if they responded prior to Week 16. Otherwise, they are censored at the date of the Week 16 injection. All participants ongoing at Week 52 and had not yet responded are censored at the date of the Week 52 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CRP</measure>
    <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
    <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Who Died During Post-Treatment Follow-Up Period</measure>
    <time_frame>Discontinuation from study treatment up to 48 weeks during follow-up period</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1041</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>120 milligrams (mg) LY2127399</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given every 4 weeks (Q4W) for 100 weeks. Participants receive a 240 mg loading dose when initiating treatment. During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).
At Weeks 16 and 52, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period.
At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg LY2127399</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given Q2W for 100 weeks. Participants receive a 180 mg loading dose when initiating treatment.
At Weeks 16 and 52, responders will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q4W for the rest of the 100-week treatment period.
At Week 16, NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Given Q2W for 52 weeks. At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 52 weeks.
At Week 52, responders are randomized to receive 1 of the 2 doses of LY2127399, with loading dose of 240 mg or 180 mg of LY2127399, followed by 120 mg of LY2127399 Q4W or 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.
At Week 16, NR will receive a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399</intervention_name>
    <description>Administered Subcutaneously (SC)</description>
    <arm_group_label>120 milligrams (mg) LY2127399</arm_group_label>
    <arm_group_label>90 mg LY2127399</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Q2W</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Q4W</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>120 milligrams (mg) LY2127399</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate is a background therapy.</description>
    <arm_group_label>120 milligrams (mg) LY2127399</arm_group_label>
    <arm_group_label>90 mg LY2127399</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years

          -  Regular use of methotrexate (MTX) in the past 12 weeks, with the dose being stable
             during the past 8 weeks

          -  At least 8 tender and swollen joints

          -  At least one erosion of a hand or foot joint observed on an X-ray

          -  An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate
             (ESR)

          -  Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP)
             antibody

          -  Woman must not be pregnant, breastfeeding, or become pregnant during the study

        Exclusion Criteria:

          -  Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6
             weeks

          -  Steroid injection or intravenous (iv) infusion in the last 6 weeks

          -  Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks

          -  History of an inadequate response to a biologic disease-modifying anti-rheumatic drug
             (DMARD)

          -  History of a serious reaction to other biological DMARDs

          -  History of the use of rituximab or other B cell therapy

          -  Use of DMARDS other than MTX, hydroxychloroquine, or sulfasalazine within the last 8
             weeks

          -  Use of leflunomide within the last 12 weeks (unless cholestyramine was used to speed
             up the elimination of leflunomide)

          -  Surgery on a joint or other major surgery less than 2 months ago, or plans to have
             joint surgery or major surgery during the study

          -  Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,
             ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition
             except RA

          -  Cervical cancer or squamous skin cancer within the past 3 years, or other cancer
             within the past 5 years

          -  Received a live vaccine received within the past 12 weeks (for example, vaccines for
             measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)

          -  Hepatitis or human immunodeficiency virus (HIV)

          -  A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months
             or a serious bone or joint infection within 6 months

          -  Symptoms of herpes zoster or herpes simplex within the last month

          -  Active or latent tuberculosis (TB)

          -  Current symptoms of a serious disorder or illness

          -  Use of an investigational drug within the last month

          -  History of the use of rituximab, any other B cell targeted biotherapy, or denosumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sanford</city>
        <state>North Carolina</state>
        <zip>27330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <zip>19460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <zip>19464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Córdoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lujan</city>
        <zip>6700</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malvern East</city>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Campinas</city>
        <zip>13059-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Caxias Do Sul</city>
        <zip>95070-560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fortaleza</city>
        <zip>60150-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goiania</city>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Juiz De Fora</city>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>São Paulo</city>
        <zip>09090780</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rousse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Opatija</city>
        <zip>51410</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rijeka</city>
        <zip>51 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1095</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Satoraljaujhely</city>
        <zip>3980</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szikszo</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ahmedabad</city>
        <zip>3800015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangalore</city>
        <zip>5600092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chennai</city>
        <zip>600100</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jaipur</city>
        <zip>302019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lucknow</city>
        <zip>226 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mysore</city>
        <zip>570023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nellore</city>
        <zip>524003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Delhi</city>
        <zip>110 076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Secunderabad</city>
        <zip>500 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Surat</city>
        <zip>395003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>284-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gunma</city>
        <zip>370-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaragi</city>
        <zip>316-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaraki</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Japan</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kagoshima</city>
        <zip>891-0133</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mie</city>
        <zip>514-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miyagi</city>
        <zip>982-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagano</city>
        <zip>380-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagasaki</city>
        <zip>857-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nara</city>
        <zip>634-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ohita</city>
        <zip>874-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okayama</city>
        <zip>710-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saga</city>
        <zip>843-0393</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>337-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sapporo-Shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>185-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toyama</city>
        <zip>933-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seongnam-Si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suwon-City</city>
        <zip>442-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Klaipedos</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kota Bahru</city>
        <zip>15586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Perak</city>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sarawak</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barrio San Mateo</city>
        <zip>52140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tijuana</city>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tauranga</city>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timaru</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dzialdowo</city>
        <zip>13-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plock</city>
        <zip>09-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wloszczowa</city>
        <zip>29-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400130</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ploiesti</city>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Khanty-Mansiysk</city>
        <zip>628012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>125299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saratov</city>
        <zip>410002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bratislava</city>
        <zip>84231</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dunajska Streda</city>
        <zip>929 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Piestany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Benoni</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Limpopo</city>
        <zip>0380</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pretoria</city>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Galle</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kalubowila</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nugegoda</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiayi</city>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuei Shan Hsiang</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Niao Sung Hsiang</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyiv</city>
        <zip>03151</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poltava</city>
        <zip>36038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sri Lanka</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>May 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2018</results_first_posted>
  <disposition_first_submitted>April 30, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 8, 2013</disposition_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study had a blinded Treatment Period 1 (Weeks 0-52), a non-blinded Treatment Period 2 (Weeks 52-100) and a post-treatment follow-up (24-48 weeks in length). All participants were assessed for nonresponse at Week 16 with non-responders (NR) defined as participants with &lt;20% improvement from baseline in both tender and swollen joint counts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>120 mg LY2127399</title>
          <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 milligrams (mg) (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered subcutaneously (SC) every 4 weeks (Q4W). For blinding purposes, participants alternated injections of LY2127399 and injections of placebo every 2 weeks (Q2W).
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
        </group>
        <group group_id="P2">
          <title>90 mg LY2127399</title>
          <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (Weeks 0-52)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="347"/>
                <participants group_id="P3" count="349"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="345"/>
                <participants group_id="P3" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 16 NR</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post-Treatment Follow-Up Population</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="303"/>
                <participants group_id="P3" count="307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70">Those who completed 52-week Treatment Period 1 including both Week 16 responders and NR.</participants>
                <participants group_id="P2" count="73">Those who completed 52-week Treatment Period 1 including both Week 16 responders and NR.</participants>
                <participants group_id="P3" count="80">Those who completed 52-week Treatment Period 1 including both Week 16 responders and NR.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="269"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="216"/>
                <participants group_id="P3" count="224"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2 (Weeks 52-100)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>120 mg LY2127399</title>
          <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
        </group>
        <group group_id="B2">
          <title>90 mg LY2127399</title>
          <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="345"/>
            <count group_id="B2" value="347"/>
            <count group_id="B3" value="349"/>
            <count group_id="B4" value="1041"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="11.8"/>
                    <measurement group_id="B2" value="52.8" spread="10.9"/>
                    <measurement group_id="B3" value="52.9" spread="11.5"/>
                    <measurement group_id="B4" value="53.2" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="292"/>
                    <measurement group_id="B4" value="877"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="411"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="588"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sri Lanka</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With American College of Rheumatology 20% Response (ACR20) at Week 24</title>
        <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response=(number of ACR20 responders) / (number of participants treated) * 100. All NR at Week 16 as well as all participants who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomized participants with evaluable ACR20 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology 20% Response (ACR20) at Week 24</title>
          <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-reactive protein (CRP). Percentage of participants achieving ACR20 response=(number of ACR20 responders) / (number of participants treated) * 100. All NR at Week 16 as well as all participants who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Week 24 endpoint.</description>
          <population>All randomized participants with evaluable ACR20 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="332"/>
                <count group_id="O3" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="32.8"/>
                    <measurement group_id="O3" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 52 in Van Der Heijde Modified Total Sharp Score (mTSS)</title>
        <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range = 0 to 220 for 44 joints) and narrowing scores (range = 0 to 168 for 42 joints) were added to obtain the mTSS (range = 0 [normal] to 388 [maximal disease]). Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 52 Weeks</time_frame>
        <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Van Der Heijde Modified Total Sharp Score (mTSS)</title>
          <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range = 0 to 220 for 44 joints) and narrowing scores (range = 0 to 168 for 42 joints) were added to obtain the mTSS (range = 0 [normal] to 388 [maximal disease]). Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.27"/>
                    <measurement group_id="O2" value="0.84" spread="0.27"/>
                    <measurement group_id="O3" value="1.57" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>All randomized participants with evaluable HAQ-DI data. Modified Baseline Observation Carried Forward (mBOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable HAQ-DI data. Modified Baseline Observation Carried Forward (mBOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.03"/>
                    <measurement group_id="O2" value="-0.30" spread="0.03"/>
                    <measurement group_id="O3" value="-0.20" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response</title>
        <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of RA. ACR50 Responder: had ≥50% improvement from baseline in both 68 tender joint (TJ) and 66 swollen joint (SJ) counts and ≥50% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response=(number (No.) of ACR50 responders) / (No. of Pts treated) * 100. ACR70 Responder: had ≥70% improvement from baseline in both TJ and SJ counts and ≥70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response= (No. of ACR70 responders) / (No. of Pts treated) * 100. All NR at Week 16 as well as all Pts who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Weeks 24 and 52 endpoints.</description>
        <time_frame>Baseline through 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable ACR50 or ACR70 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response</title>
          <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of RA. ACR50 Responder: had ≥50% improvement from baseline in both 68 tender joint (TJ) and 66 swollen joint (SJ) counts and ≥50% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of Pt achieving ACR50 response=(number (No.) of ACR50 responders) / (No. of Pts treated) * 100. ACR70 Responder: had ≥70% improvement from baseline in both TJ and SJ counts and ≥70% improvement in at least 3 of same 5 criteria for ACR50. Percentage of Pts achieving ACR70 response= (No. of ACR70 responders) / (No. of Pts treated) * 100. All NR at Week 16 as well as all Pts who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Weeks 24 and 52 endpoints.</description>
          <population>All randomized participants with evaluable ACR50 or ACR70 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="332"/>
                <count group_id="O3" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Based on 28 Joint Count and C-Reactive Protein Level (DAS28-CRP)</title>
        <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and participant's global assessment of disease activity using visual analog scale (VAS) (participant global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable DAS28-CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Based on 28 Joint Count and C-Reactive Protein Level (DAS28-CRP)</title>
          <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and participant's global assessment of disease activity using visual analog scale (VAS) (participant global VAS). DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*participant global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable DAS28-CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.07"/>
                    <measurement group_id="O2" value="-1.00" spread="0.07"/>
                    <measurement group_id="O3" value="-0.78" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.07"/>
                    <measurement group_id="O2" value="-1.00" spread="0.07"/>
                    <measurement group_id="O3" value="-0.80" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With DAS28-CRP Based European League Against Rheumatism (EULAR) Response</title>
        <description>EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or NR based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: &gt;5.1 or &lt;0.6 improvement from baseline). Percentage of participants with DAS28-CRP based EULAR response =(number of participants with specific response) / (number of participants analyzed in the group) * 100.</description>
        <time_frame>Baseline through 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable EULAR response data. Modified last observation carried forward (mLOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DAS28-CRP Based European League Against Rheumatism (EULAR) Response</title>
          <description>EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP &gt;5.1, low disease activity: DAS28-CRP &lt;3.2, and remission: DAS28-CRP &lt;2.6. Participants are categorized as EULAR responders or NR based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: &gt;5.1 or &lt;0.6 improvement from baseline). Percentage of participants with DAS28-CRP based EULAR response =(number of participants with specific response) / (number of participants analyzed in the group) * 100.</description>
          <population>All randomized participants with evaluable EULAR response data. Modified last observation carried forward (mLOCF) was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24- Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="45.3"/>
                    <measurement group_id="O3" value="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="39.1"/>
                    <measurement group_id="O3" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 - No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Domain Scores and Summary Scores</title>
        <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (CS), physical CS (PCS) and mental CS (MCS). Domain scores were calculated by summing each item for each domain and transforming scores into a 0-100 scale. Higher scores indicated better health status. If &lt; 50% of the questions within a domain were answered, raw scores were not calculated. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100. Higher score indicated better mental or physical health. LS means were calculated using ANCOVA with treatment, region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable SF-36 domain and summary scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Domain Scores and Summary Scores</title>
          <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, 2 component scores (CS), physical CS (PCS) and mental CS (MCS). Domain scores were calculated by summing each item for each domain and transforming scores into a 0-100 scale. Higher scores indicated better health status. If &lt; 50% of the questions within a domain were answered, raw scores were not calculated. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100. Higher score indicated better mental or physical health. LS means were calculated using ANCOVA with treatment, region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable SF-36 domain and summary scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="0.48"/>
                    <measurement group_id="O2" value="3.16" spread="0.47"/>
                    <measurement group_id="O3" value="2.06" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.50"/>
                    <measurement group_id="O2" value="3.22" spread="0.49"/>
                    <measurement group_id="O3" value="1.82" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" spread="0.46"/>
                    <measurement group_id="O2" value="4.08" spread="0.45"/>
                    <measurement group_id="O3" value="2.52" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="0.47"/>
                    <measurement group_id="O2" value="4.48" spread="0.46"/>
                    <measurement group_id="O3" value="2.32" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RL - physical problems - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="0.46"/>
                    <measurement group_id="O2" value="3.64" spread="0.46"/>
                    <measurement group_id="O3" value="1.99" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RL - physical problems - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" spread="0.47"/>
                    <measurement group_id="O2" value="3.79" spread="0.46"/>
                    <measurement group_id="O3" value="1.82" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RL - emotional problems- Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="0.60"/>
                    <measurement group_id="O2" value="4.81" spread="0.59"/>
                    <measurement group_id="O3" value="2.91" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RL - emotional problems- Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="0.61"/>
                    <measurement group_id="O2" value="4.34" spread="0.59"/>
                    <measurement group_id="O3" value="2.56" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH Perception - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="0.41"/>
                    <measurement group_id="O2" value="3.72" spread="0.40"/>
                    <measurement group_id="O3" value="2.54" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH Perception - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="0.42"/>
                    <measurement group_id="O2" value="3.41" spread="0.41"/>
                    <measurement group_id="O3" value="2.18" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="0.53"/>
                    <measurement group_id="O2" value="4.47" spread="0.53"/>
                    <measurement group_id="O3" value="3.28" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" spread="0.55"/>
                    <measurement group_id="O2" value="4.37" spread="0.54"/>
                    <measurement group_id="O3" value="3.10" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.53"/>
                    <measurement group_id="O2" value="4.18" spread="0.52"/>
                    <measurement group_id="O3" value="2.79" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="0.53"/>
                    <measurement group_id="O2" value="3.99" spread="0.52"/>
                    <measurement group_id="O3" value="2.87" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="0.50"/>
                    <measurement group_id="O2" value="4.41" spread="0.49"/>
                    <measurement group_id="O3" value="2.99" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="0.51"/>
                    <measurement group_id="O2" value="3.96" spread="0.50"/>
                    <measurement group_id="O3" value="3.02" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="0.43"/>
                    <measurement group_id="O2" value="3.08" spread="0.43"/>
                    <measurement group_id="O3" value="1.76" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.44"/>
                    <measurement group_id="O2" value="3.30" spread="0.43"/>
                    <measurement group_id="O3" value="1.55" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.56"/>
                    <measurement group_id="O2" value="4.74" spread="0.55"/>
                    <measurement group_id="O3" value="3.33" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="319"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="0.57"/>
                    <measurement group_id="O2" value="4.27" spread="0.56"/>
                    <measurement group_id="O3" value="3.22" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Fatigue Inventory (BFI) Individual Items and Impact Score</title>
        <description>The BFI is a brief participant-reported questionnaire for the rapid assessment of fatigue severity and the impact of fatigue on daily functioning in the past 24 hours. The BFI contains 10 items; however, Item 1 is not included in the scoring of the scale as it asks about usual fatigue over the past week with the participant answering 'yes' or 'no'. The remaining 9 items assess fatigue severity (3 items) and impact of fatigue on daily functioning (6 items) using an 11-point numeric scale, with 0=no fatigue and 10=fatigue as bad as you can imagine. The fatigue impact subscale score is the average of the non-missing responses to 6 items: general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. If more than 3 items within the fatigue impact subscale were not answered by a participant, the subscale is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable BFI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Fatigue Inventory (BFI) Individual Items and Impact Score</title>
          <description>The BFI is a brief participant-reported questionnaire for the rapid assessment of fatigue severity and the impact of fatigue on daily functioning in the past 24 hours. The BFI contains 10 items; however, Item 1 is not included in the scoring of the scale as it asks about usual fatigue over the past week with the participant answering 'yes' or 'no'. The remaining 9 items assess fatigue severity (3 items) and impact of fatigue on daily functioning (6 items) using an 11-point numeric scale, with 0=no fatigue and 10=fatigue as bad as you can imagine. The fatigue impact subscale score is the average of the non-missing responses to 6 items: general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. If more than 3 items within the fatigue impact subscale were not answered by a participant, the subscale is set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable BFI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue-Now - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.14"/>
                    <measurement group_id="O2" value="-1.12" spread="0.13"/>
                    <measurement group_id="O3" value="-0.61" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Now - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.14"/>
                    <measurement group_id="O2" value="-1.01" spread="0.13"/>
                    <measurement group_id="O3" value="-0.56" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Usual - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.13"/>
                    <measurement group_id="O2" value="-1.06" spread="0.13"/>
                    <measurement group_id="O3" value="-0.61" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Usual - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.14"/>
                    <measurement group_id="O2" value="-0.97" spread="0.13"/>
                    <measurement group_id="O3" value="-0.66" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Worst - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.14"/>
                    <measurement group_id="O2" value="-1.22" spread="0.14"/>
                    <measurement group_id="O3" value="-0.71" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-Worst - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.15"/>
                    <measurement group_id="O2" value="-1.19" spread="0.14"/>
                    <measurement group_id="O3" value="-0.81" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.14"/>
                    <measurement group_id="O2" value="-1.09" spread="0.13"/>
                    <measurement group_id="O3" value="-0.61" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.14"/>
                    <measurement group_id="O2" value="-1.07" spread="0.13"/>
                    <measurement group_id="O3" value="-0.61" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.14"/>
                    <measurement group_id="O2" value="-1.01" spread="0.14"/>
                    <measurement group_id="O3" value="-0.47" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.14"/>
                    <measurement group_id="O2" value="-0.82" spread="0.14"/>
                    <measurement group_id="O3" value="-0.53" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Ability - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.15"/>
                    <measurement group_id="O2" value="-1.02" spread="0.14"/>
                    <measurement group_id="O3" value="-0.44" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Ability - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.14"/>
                    <measurement group_id="O2" value="-0.98" spread="0.14"/>
                    <measurement group_id="O3" value="-0.45" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Work - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.14"/>
                    <measurement group_id="O2" value="-1.07" spread="0.14"/>
                    <measurement group_id="O3" value="-0.48" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Work - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.14"/>
                    <measurement group_id="O2" value="-1.00" spread="0.14"/>
                    <measurement group_id="O3" value="-0.52" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations with Other - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.14"/>
                    <measurement group_id="O2" value="-0.64" spread="0.14"/>
                    <measurement group_id="O3" value="-0.13" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations with Other - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.14"/>
                    <measurement group_id="O2" value="-0.46" spread="0.14"/>
                    <measurement group_id="O3" value="-0.16" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Life - Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.15"/>
                    <measurement group_id="O2" value="-0.82" spread="0.15"/>
                    <measurement group_id="O3" value="-0.36" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Life - Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.15"/>
                    <measurement group_id="O2" value="-0.74" spread="0.14"/>
                    <measurement group_id="O3" value="-0.46" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Impact Subscale- Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.13"/>
                    <measurement group_id="O2" value="-0.93" spread="0.13"/>
                    <measurement group_id="O3" value="-0.42" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Impact Subscale- Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.13"/>
                    <measurement group_id="O2" value="-0.83" spread="0.13"/>
                    <measurement group_id="O3" value="-0.46" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duration of Morning Stiffness (Minutes)</title>
        <description>The Investigator asks participants about the duration of their morning stiffness (in minutes) in and around the joints and records the duration. The Investigator should ask the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration is longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable morning stiffness data; mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duration of Morning Stiffness (Minutes)</title>
          <description>The Investigator asks participants about the duration of their morning stiffness (in minutes) in and around the joints and records the duration. The Investigator should ask the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration is longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable morning stiffness data; mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="318"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.2" spread="5.0"/>
                    <measurement group_id="O2" value="-32.0" spread="4.8"/>
                    <measurement group_id="O3" value="-34.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="319"/>
                    <count group_id="O3" value="314"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.4" spread="5.2"/>
                    <measurement group_id="O2" value="-31.2" spread="5.0"/>
                    <measurement group_id="O3" value="-37.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory Short Form (BPI-SF) Individual Items and Interference Scores</title>
        <description>The BPI-SF is a self-reported scale that measures the severity of pain based on the worst pain, least pain, average pain experienced during the past 24-hours and pain based on the pain right now with scores ranging from 0 (no pain) to 10 (pain as severe as you can imagine). Pain interference score is the average of the responses in past 24-hours to 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life [each item scored from 0 (does not interfere) to 10 (completely interferes)]. If more than 3 items of the Pain Interference Score are not answered by a participant, the score were set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable BPI-SF scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory Short Form (BPI-SF) Individual Items and Interference Scores</title>
          <description>The BPI-SF is a self-reported scale that measures the severity of pain based on the worst pain, least pain, average pain experienced during the past 24-hours and pain based on the pain right now with scores ranging from 0 (no pain) to 10 (pain as severe as you can imagine). Pain interference score is the average of the responses in past 24-hours to 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life [each item scored from 0 (does not interfere) to 10 (completely interferes)]. If more than 3 items of the Pain Interference Score are not answered by a participant, the score were set to missing. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable BPI-SF scores. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain-Worst - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.1"/>
                    <measurement group_id="O2" value="-1.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-Worst - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.1"/>
                    <measurement group_id="O2" value="-1.3" spread="0.1"/>
                    <measurement group_id="O3" value="-0.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-Least - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.1"/>
                    <measurement group_id="O2" value="-0.6" spread="0.1"/>
                    <measurement group_id="O3" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-Least - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.1"/>
                    <measurement group_id="O2" value="-0.6" spread="0.1"/>
                    <measurement group_id="O3" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-Average - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.1"/>
                    <measurement group_id="O2" value="-0.9" spread="0.1"/>
                    <measurement group_id="O3" value="-0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-Average - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.1"/>
                    <measurement group_id="O2" value="-1.0" spread="0.1"/>
                    <measurement group_id="O3" value="-0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-Now - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.1"/>
                    <measurement group_id="O2" value="-1.2" spread="0.1"/>
                    <measurement group_id="O3" value="-0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-Now - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.1"/>
                    <measurement group_id="O2" value="-1.3" spread="0.1"/>
                    <measurement group_id="O3" value="-0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.1"/>
                    <measurement group_id="O2" value="-1.0" spread="0.1"/>
                    <measurement group_id="O3" value="-0.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.1"/>
                    <measurement group_id="O2" value="-1.2" spread="0.1"/>
                    <measurement group_id="O3" value="-0.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.1"/>
                    <measurement group_id="O2" value="-1.0" spread="0.1"/>
                    <measurement group_id="O3" value="-0.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.1"/>
                    <measurement group_id="O2" value="-1.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Ability - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.1"/>
                    <measurement group_id="O2" value="-1.2" spread="0.1"/>
                    <measurement group_id="O3" value="-0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Ability - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.1"/>
                    <measurement group_id="O2" value="-1.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Work - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.1"/>
                    <measurement group_id="O2" value="-1.0" spread="0.1"/>
                    <measurement group_id="O3" value="-0.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Work - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.1"/>
                    <measurement group_id="O2" value="-1.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations with Other - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.1"/>
                    <measurement group_id="O2" value="-0.6" spread="0.1"/>
                    <measurement group_id="O3" value="-0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations with Other - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.1"/>
                    <measurement group_id="O2" value="-0.5" spread="0.1"/>
                    <measurement group_id="O3" value="-0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.1"/>
                    <measurement group_id="O2" value="-1.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.1"/>
                    <measurement group_id="O2" value="-1.0" spread="0.1"/>
                    <measurement group_id="O3" value="-0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Life - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.1"/>
                    <measurement group_id="O2" value="-1.2" spread="0.1"/>
                    <measurement group_id="O3" value="-0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Life - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.1"/>
                    <measurement group_id="O2" value="-1.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference Score - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.12"/>
                    <measurement group_id="O2" value="-1.02" spread="0.12"/>
                    <measurement group_id="O3" value="-0.50" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference Score - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.12"/>
                    <measurement group_id="O2" value="-1.00" spread="0.12"/>
                    <measurement group_id="O3" value="-0.58" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Clinical Response (MCR) During 52 Weeks</title>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Zero participants analyzed. Per protocol and statistical analysis plan (SAP) amendments, the major clinical response classification was not collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Clinical Response (MCR) During 52 Weeks</title>
          <population>Zero participants analyzed. Per protocol and statistical analysis plan (SAP) amendments, the major clinical response classification was not collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Change From Baseline in mTSS Less Than or Equal to (≤) 0</title>
        <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range = 0 [normal] to 388 [maximal disease]). Percentage of participants = (number of participants with mTSS ≤0 at Week 24) / (total number of participants analyzed in the group) * 100.</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change From Baseline in mTSS Less Than or Equal to (≤) 0</title>
          <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range = 0 [normal] to 388 [maximal disease]). Percentage of participants = (number of participants with mTSS ≤0 at Week 24) / (total number of participants analyzed in the group) * 100.</description>
          <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                    <measurement group_id="O2" value="61.8"/>
                    <measurement group_id="O3" value="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in B Cell Subset Counts</title>
        <description>B cell subset counts are: cluster designation (CD)19+ B cell counts, Immature/transitional [CD19+immunoglobulin D (IgD)-CD27-], Mature naïve (CD19+IgD+CD27-), Non-switched memory (CD19+IgD+CD27+) and Memory (CD19+IgD-CD27+). A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants with evaluable B cell subset counts data. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in B Cell Subset Counts</title>
          <description>B cell subset counts are: cluster designation (CD)19+ B cell counts, Immature/transitional [CD19+immunoglobulin D (IgD)-CD27-], Mature naïve (CD19+IgD+CD27-), Non-switched memory (CD19+IgD+CD27+) and Memory (CD19+IgD-CD27+). A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable B cell subset counts data. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>cells/microliter (cells/µL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="333"/>
                <count group_id="O3" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD19+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="333"/>
                    <count group_id="O3" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.1" spread="4.9"/>
                    <measurement group_id="O2" value="-60.9" spread="4.9"/>
                    <measurement group_id="O3" value="0.7" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+IgD-CD27-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="0.7"/>
                    <measurement group_id="O2" value="-3.9" spread="0.7"/>
                    <measurement group_id="O3" value="0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+IgD+CD27-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-89.4" spread="3.3"/>
                    <measurement group_id="O2" value="-92.4" spread="3.3"/>
                    <measurement group_id="O3" value="-3.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+IgD+CD27+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="1.0"/>
                    <measurement group_id="O2" value="8.9" spread="1.0"/>
                    <measurement group_id="O3" value="1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+IgD-CD27+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="1.9"/>
                    <measurement group_id="O2" value="20.6" spread="1.8"/>
                    <measurement group_id="O3" value="3.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics (PK): Constant Clearance</title>
        <description>Population estimate of constant clearance as determined by population PK analysis. A 2-compartment model was used in PK modeling. Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of LY2127399 with evaluable LY2127399 PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2127399</title>
            <description>A loading dose of 240 mg (2 injections of 120 mg) of LY2127399 followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 100 weeks or a loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 100 weeks. At Weeks 16 and 52, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period or 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics (PK): Constant Clearance</title>
          <description>Population estimate of constant clearance as determined by population PK analysis. A 2-compartment model was used in PK modeling. Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.</description>
          <population>All randomized participants who received at least 1 dose of LY2127399 with evaluable LY2127399 PK data.</population>
          <units>milliliter per hour (mL/h)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" lower_limit="3.46" upper_limit="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-LY2127399 Antibodies</title>
        <description>Participants with treatment-emergent anti-drug antibodies (ADA) were participants who had any sample from baseline up to and through Week 24 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). Percentage of participants with ADA=(number of participants with treatment-emergent ADA) / (number of participants assessed) * 100.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug with an evaluable baseline ADA result and a post-baseline ADA result. Participants missing an evaluable baseline result with all negative post-baseline results were included. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-LY2127399 Antibodies</title>
          <description>Participants with treatment-emergent anti-drug antibodies (ADA) were participants who had any sample from baseline up to and through Week 24 that was a 4-fold increase (2-dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). Percentage of participants with ADA=(number of participants with treatment-emergent ADA) / (number of participants assessed) * 100.</description>
          <population>All randomized participants who received at least 1 dose of study drug with an evaluable baseline ADA result and a post-baseline ADA result. Participants missing an evaluable baseline result with all negative post-baseline results were included. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="344"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No Structural Progression at Week 52</title>
        <description>No structural progression is defined as the change in mTSS from baseline ≤0. The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). Percentage of participants=(number of participants with mTSS ≤0 at Week 52) / (total number of participants analyzed in the group) * 100.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No Structural Progression at Week 52</title>
          <description>No structural progression is defined as the change in mTSS from baseline ≤0. The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). Percentage of participants=(number of participants with mTSS ≤0 at Week 52) / (total number of participants analyzed in the group) * 100.</description>
          <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="57.6"/>
                    <measurement group_id="O3" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in mTSS</title>
        <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in mTSS</title>
          <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.14"/>
                    <measurement group_id="O2" value="0.45" spread="0.14"/>
                    <measurement group_id="O3" value="0.82" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Immunoglobulin (Ig) Levels</title>
        <description>Immunoglobulins (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in Ig levels. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants with evaluable serum Ig data. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Immunoglobulin (Ig) Levels</title>
          <description>Immunoglobulins (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) levels are reported. A negative change indicated a decrease in Ig levels. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable serum Ig data. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>grams/liter (g/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="342"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.380" spread="0.028"/>
                    <measurement group_id="O2" value="-0.382" spread="0.028"/>
                    <measurement group_id="O3" value="-0.009" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.375" spread="0.096"/>
                    <measurement group_id="O2" value="-1.235" spread="0.097"/>
                    <measurement group_id="O3" value="-0.176" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.235" spread="0.016"/>
                    <measurement group_id="O2" value="-0.274" spread="0.016"/>
                    <measurement group_id="O3" value="-0.032" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Joint Space Narrowing Score and Bone Erosions Score (Components of mTSS)</title>
        <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Joint Space Narrowing Score and Bone Erosions Score (Components of mTSS)</title>
          <description>The mTSS quantifies the extent of bone erosions and joint space narrowing for 44 and 42 joints. X-rays of the hands/wrists and feet are scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosions scores (range=0 to 220 for 44 joints) and narrowing scores (range=0 to 168 for 42 joints) were added to obtain the mTSS (range=0 [normal] to 388 [maximal disease]). LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable mTSS data. A linear extrapolation method was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Joint Space Narrowing - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.09"/>
                    <measurement group_id="O2" value="0.19" spread="0.09"/>
                    <measurement group_id="O3" value="0.34" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Space Narrowing - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.16"/>
                    <measurement group_id="O2" value="0.35" spread="0.16"/>
                    <measurement group_id="O3" value="0.61" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Erosions - Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.09"/>
                    <measurement group_id="O2" value="0.26" spread="0.08"/>
                    <measurement group_id="O3" value="0.48" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Erosions - Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.17"/>
                    <measurement group_id="O2" value="0.49" spread="0.17"/>
                    <measurement group_id="O3" value="0.96" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology Percent Improvement (ACR-N)</title>
        <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of either a) % change in TJ count, b) % change in SJ count, or c) the median % change of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater % improvement) and negative scores indicate a decline. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline DAS28-CRP as a covariate.</description>
        <time_frame>Baseline through 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable ACR-N data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology Percent Improvement (ACR-N)</title>
          <description>ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of either a) % change in TJ count, b) % change in SJ count, or c) the median % change of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to range of -100 to 100 to minimize impact of outliers (greater values indicate greater % improvement) and negative scores indicate a decline. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline DAS28-CRP as a covariate.</description>
          <population>All randomized participants with evaluable ACR-N data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of improvement</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.5"/>
                    <measurement group_id="O2" value="2.1" spread="2.5"/>
                    <measurement group_id="O3" value="-6.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.5"/>
                    <measurement group_id="O2" value="0.3" spread="2.5"/>
                    <measurement group_id="O3" value="-7.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Count (68 Joint Count)</title>
        <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable tender joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count (68 Joint Count)</title>
          <description>Tender joint count is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable tender joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>joint counts</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.41" spread="0.72"/>
                    <measurement group_id="O2" value="-7.88" spread="0.72"/>
                    <measurement group_id="O3" value="-6.40" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.88" spread="0.73"/>
                    <measurement group_id="O2" value="-8.09" spread="0.73"/>
                    <measurement group_id="O3" value="-5.72" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Count (66 Joint Count)</title>
        <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable swollen joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count (66 Joint Count)</title>
          <description>Swollen joint count is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable swollen joint count data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>joint counts</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.38" spread="0.49"/>
                    <measurement group_id="O2" value="-5.64" spread="0.49"/>
                    <measurement group_id="O3" value="-4.67" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.10" spread="0.49"/>
                    <measurement group_id="O2" value="-5.53" spread="0.49"/>
                    <measurement group_id="O3" value="-4.61" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Assessment of Pain [Visual Analog Scale (VAS)]</title>
        <description>Participant's assessment of their current arthritis pain using VAS ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable participant's assessment of pain data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Assessment of Pain [Visual Analog Scale (VAS)]</title>
          <description>Participant's assessment of their current arthritis pain using VAS ranged from 0 millimeters (mm) (no pain) to 100 mm (worst possible pain). A decrease in pain score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable participant's assessment of pain data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="1.2"/>
                    <measurement group_id="O2" value="-14.6" spread="1.2"/>
                    <measurement group_id="O3" value="-9.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" spread="1.2"/>
                    <measurement group_id="O2" value="-14.6" spread="1.2"/>
                    <measurement group_id="O3" value="-8.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant's Global Assessment of Disease Activity (VAS)</title>
        <description>Participant's assessment of their current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable participant's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant's Global Assessment of Disease Activity (VAS)</title>
          <description>Participant's assessment of their current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable participant's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" spread="1.2"/>
                    <measurement group_id="O2" value="-15.1" spread="1.2"/>
                    <measurement group_id="O3" value="-11.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="1.2"/>
                    <measurement group_id="O2" value="-15.2" spread="1.2"/>
                    <measurement group_id="O3" value="-10.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity (VAS)</title>
        <description>Physician's assessment of the participant's current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable physician's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity (VAS)</title>
          <description>Physician's assessment of the participant's current arthritis disease activity using VAS ranged from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). A decrease in disease activity score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable physician's global assessment of disease activity data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="1.3"/>
                    <measurement group_id="O2" value="-22.0" spread="1.3"/>
                    <measurement group_id="O3" value="-17.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="1.3"/>
                    <measurement group_id="O2" value="-20.6" spread="1.3"/>
                    <measurement group_id="O3" value="-17.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in HAQ-DI</title>
        <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants with evaluable HAQ-DI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in HAQ-DI</title>
          <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable HAQ-DI data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.03"/>
                    <measurement group_id="O2" value="-0.30" spread="0.03"/>
                    <measurement group_id="O3" value="-0.18" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Absolute B Cell Counts</title>
        <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants with evaluable CD3-CD20+ B cell counts. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Absolute B Cell Counts</title>
          <description>Cell-surface marker cluster designation (CD) 3 negative, CD20 positive (CD3-CD20+) defines total mature B cells. B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. A positive or negative change indicated an increase or decrease, respectively in B cell count. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable CD3-CD20+ B cell counts. mLOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>cells/microliter (cells/µL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="344"/>
                <count group_id="O3" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.5" spread="4.5"/>
                    <measurement group_id="O2" value="-58.6" spread="4.5"/>
                    <measurement group_id="O3" value="-6.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ACR20 at Week 52</title>
        <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, HAQ-DI (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of participants achieving ACR20 response=(number of ACR20 responders) /( number of participants treated) * 100. All NR at Week 16 as well as all participants who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Week 52 endpoint.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants with evaluable ACR20 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ACR20 at Week 52</title>
          <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, HAQ-DI (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and CRP. Percentage of participants achieving ACR20 response=(number of ACR20 responders) /( number of participants treated) * 100. All NR at Week 16 as well as all participants who discontinued study treatment at any time for any reason were defined as NR starting at that time-point and going forward, including Week 52 endpoint.</description>
          <population>All randomized participants with evaluable ACR20 responder data. If participant's CRP was missing, last post-baseline value was used. If ACR was missing after carrying forward CRP, last post-baseline ACR response was used. Data after Week 16 for Week 16 NR were not included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="332"/>
                <count group_id="O3" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="9.6"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to ACR20 Response</title>
        <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, HAQ-DI (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and CRP. The Kaplan-Meier was used to estimate time to ACR20 response over the Treatment Period (52 weeks). Time to ACR20 response = (Date of the first post-baseline visit during the Treatment Period meeting ACR20 response criteria - Date of first injection of study treatment + 1) / 7. Week 16 NR are counted as responders if they responded prior to Week 16. Otherwise, they are censored at the date of the Week 16 injection. All participants ongoing at Week 52 and had not yet responded are censored at the date of the Week 52 visit.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants with evaluable ACR20 responder data. The number of participants censored are 128 (120 mg LY2127399), 123 (90 mg LY2127399) and 162 (placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to ACR20 Response</title>
          <description>ACR Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA). ACR20 Responder: had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, HAQ-DI (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and CRP. The Kaplan-Meier was used to estimate time to ACR20 response over the Treatment Period (52 weeks). Time to ACR20 response = (Date of the first post-baseline visit during the Treatment Period meeting ACR20 response criteria - Date of first injection of study treatment + 1) / 7. Week 16 NR are counted as responders if they responded prior to Week 16. Otherwise, they are censored at the date of the Week 16 injection. All participants ongoing at Week 52 and had not yet responded are censored at the date of the Week 52 visit.</description>
          <population>All randomized participants with evaluable ACR20 responder data. The number of participants censored are 128 (120 mg LY2127399), 123 (90 mg LY2127399) and 162 (placebo).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="12.1" upper_limit="16.4"/>
                    <measurement group_id="O2" value="16.1" lower_limit="12.3" upper_limit="20.0"/>
                    <measurement group_id="O3" value="20.1" lower_limit="16.4" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CRP</title>
        <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
        <time_frame>Baseline, 24 weeks and 52 weeks</time_frame>
        <population>All randomized participants with evaluable CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CRP</title>
          <description>CRP is an indicator of inflammation. A negative change indicated an improvement in the participant's condition. LS means were calculated using ANCOVA with treatment and region as fixed factors and baseline as a covariate.</description>
          <population>All randomized participants with evaluable CRP data. mBOCF was used to impute missing post-baseline values. Data after Week 16 for Week 16 NR were not included.</population>
          <units>milligrams/liter (mg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.30" spread="0.83"/>
                    <measurement group_id="O2" value="-2.03" spread="0.84"/>
                    <measurement group_id="O3" value="-0.54" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="0.96"/>
                    <measurement group_id="O2" value="-2.04" spread="0.97"/>
                    <measurement group_id="O3" value="-0.40" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Died During Post-Treatment Follow-Up Period</title>
        <time_frame>Discontinuation from study treatment up to 48 weeks during follow-up period</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and entered post-treatment follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 240 mg (2 injections of 120 mg) of LY2127399, followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>90 mg LY2127399</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W.
At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, Week 16 responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Period 1 (Weeks 0-52): A loading dose of 2 injections of placebo, followed by maintenance dosing of 1 injection of placebo administered SC Q2W.
At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
Treatment Period 2 (Weeks 52-100): At Week 52, responders were randomized to receive either 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2 or 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died During Post-Treatment Follow-Up Period</title>
          <population>All randomized participants who received at least 1 dose of study drug and entered post-treatment follow-up period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY 120 mg Q4W, Randomized Treatment Period 1</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 52 weeks during Treatment Period 1. At Week 16, responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 52-week Treatment Period 1. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
The Randomized Treatment Period 1 was defined as the time all data was collected during the Treatment Period 1, excluding the data collected after the date of the Week 16 injection for the Week 16 NR.</description>
        </group>
        <group group_id="E2">
          <title>LY 90 mg Q2W, Randomized Treatment Period 1</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, responders received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
The Randomized Treatment Period 1 was defined as the time all data was collected during the Treatment Period 1, excluding the data collected after the date of the Week 16 injection for the Week 16 NR.</description>
        </group>
        <group group_id="E3">
          <title>Placebo, Randomized Treatment Period 1</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
The Randomized Treatment Period 1 was defined as the time all data was collected during the Treatment Period 1, excluding the data collected after the date of the Week 16 injection for the Week 16 NR.</description>
        </group>
        <group group_id="E4">
          <title>LY 120 mg Q4W to LY 90 mg Q2W (Week 16), Rescue Period</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 16 weeks during Treatment Period 1. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 52-week Treatment Period 1.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the Treatment Period 1 for Week 16 NR.</description>
        </group>
        <group group_id="E5">
          <title>LY 90 mg Q2W, Rescue Period</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 16 weeks during Treatment Period 1.
At Week 16, NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 52-week Treatment Period 1.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the Treatment Period 1 for Week 16 NR.</description>
        </group>
        <group group_id="E6">
          <title>Placebo to LY 90 mg Q2W (Week 16), Rescue Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 16 weeks during Treatment Period 1.
At Week 16, NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 52-week Treatment Period 1.
The Rescue Treatment Period was defined as all data collected after the date of the Week 16 injection during the Treatment Period 1 for Week 16 NR.</description>
        </group>
        <group group_id="E7">
          <title>LY 120 mg Q4W, Treatment Period 2</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 52 weeks during Treatment Period 1. At Week 16, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 52-week Treatment Period 1. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
Treatment Period 2 was defined as all data collected from Week 52 to Week 100 during non-blinded Treatment Period 2.</description>
        </group>
        <group group_id="E8">
          <title>LY 90 mg Q2W, Treatment Period 2</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, both Week 16 responders and NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
At Week 52, both Week 16 responders and NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
Treatment Period 2 was defined as all data collected from Week 52 to Week 100 during non-blinded Treatment Period 2.</description>
        </group>
        <group group_id="E9">
          <title>Placebo to LY 120 mg Q4W (Week 52), Treatment Period 2</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, Week 16 responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
At Week 52, Week 16 responders were randomized to receive 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2
Treatment Period 2 was defined as all data collected from Week 52 to Week 100 during non-blinded Treatment Period 2.</description>
        </group>
        <group group_id="E10">
          <title>Placebo to LY 90 mg Q2W (Week 52), Treatment Period 2</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, Week 16 responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
At Week 52, Week 16 responders were randomized to receive 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q4W for the rest of the Treatment Period 2
Treatment Period 2 was defined as all data collected from Week 52 to Week 100 during non-blinded Treatment Period 2.</description>
        </group>
        <group group_id="E11">
          <title>LY 120 mg Q4W to LY 90 mg Q2W (Week 16), Treatment Period 2</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 16 weeks during Treatment Period 1. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, Week 16 NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 52-week Treatment Period 1.
During non-blinded Treatment Period 2, Week 16 NR received 1 injection of 90 mg of LY2127399.
Treatment Period 2 was defined as all data collected from Week 52 to Week 100 during non-blinded Treatment Period 2.</description>
        </group>
        <group group_id="E12">
          <title>Placebo to LY 90 mg Q2W (Week 16), Treatment Period 2</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 16 weeks during Treatment Period 1.
At Week 16, Week 16 NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 52-week Treatment Period 1.
During non-blinded Treatment Period 2, Week 16 NR received 1 injection of 90 mg of LY2127399.
Treatment Period 2 was defined as all data collected from Week 52 to Week 100 during non-blinded Treatment Period 2.</description>
        </group>
        <group group_id="E13">
          <title>LY 120 mg Q4W, Follow-up Period</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 52 weeks during Treatment Period 1. At Week 16, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 52-week Treatment Period 1. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 52, Week 16 responders received 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2.
The Post-Treatment Follow-Up Period started after Week 100 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E14">
          <title>LY 90 mg Q2W, Follow-up Period</title>
          <description>A loading dose of 180 mg of LY2127399 (2 injections of 90 mg) followed by maintenance dosing of 90 mg of LY2127399 administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, both Week 16 responders and NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 1.
At Week 52, both Week 16 responders and NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the Treatment Period 2.
The Post-Treatment Follow-Up Period started after Week 100 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E15">
          <title>Placebo to LY 120 mg Q4W (Week 52), Follow-up Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, Week 16 responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
At Week 52, Week 16 responders were randomized to receive 2 injections of 120 mg of LY2127399, followed by 120 mg of LY2127399 Q4W for the rest of the Treatment Period 2
The Post-Treatment Follow-Up Period started after Week 100 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E16">
          <title>Placebo to LY 90 mg Q2W (Week 52), Follow-up Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, Week 16 responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
At Week 52, Week 16 responders were randomized to receive 2 injections of 90 mg of LY2127399, followed by 90 mg of LY2127399 Q4W for the rest of the Treatment Period 2
The Post-Treatment Follow-Up Period started after Week 100 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E17">
          <title>LY 120 mg Q4W to LY 90 mg Q2W (Week 16), Follow-up Period</title>
          <description>A loading dose of 240 mg of LY2127399 (2 injections of 120 mg) followed by maintenance dosing of 120 mg of LY2127399 administered SC Q4W for 16 weeks during Treatment Period 1. For blinding purposes, participants alternated injections of LY2127399 and injections of placebo Q2W.
At Week 16, Week 16 NR received 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 52-week Treatment Period 1.
During non-blinded Treatment Period 2, Week 16 NR received 1 injection of 90 mg of LY2127399.
The Post-Treatment Follow-Up Period started after Week 100 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E18">
          <title>Placebo to LY 90 mg Q2W (Week 16), Follow-up Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 16 weeks during Treatment Period 1.
At Week 16, Week 16 NR received a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 52-week Treatment Period 1.
During non-blinded Treatment Period 2, Week 16 NR received 1 injection of 90 mg of LY2127399.
The Post-Treatment Follow-Up Period started after Week 100 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
        <group group_id="E19">
          <title>Placebo, Follow-up Period</title>
          <description>A loading dose of 2 injections of placebo followed by maintenance dosing of placebo administered SC Q2W for 52 weeks during Treatment Period 1. At Week 16, responders received 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the Treatment Period 1.
The Post-Treatment Follow-Up Period started after Week 52 or the early discontinuation visit and lasted up to 48 weeks following the last injection of study treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="345"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="348"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="303"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E19" subjects_affected="14" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Infective tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="4" subjects_affected="4" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma stage i</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Radiculitis lumbosacral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="345"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="348"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="58"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="57"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="43" subjects_at_risk="241"/>
                <counts group_id="E14" subjects_affected="39" subjects_at_risk="303"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E19" subjects_affected="26" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="3" subjects_affected="3" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="345"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="345"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="345"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="345"/>
                <counts group_id="E3" events="34" subjects_affected="25" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="8" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E14" events="9" subjects_affected="7" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="5" subjects_affected="5" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="345"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E14" events="5" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E19" events="5" subjects_affected="5" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="345"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="345"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E4" events="8" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Bunion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="345"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="348"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="3" subjects_affected="3" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study has been terminated not based on safety concerns, but due to insufficient efficacy. Early termination led to lower than expected enrollment and was responsible for the large number of discontinuation reason as Sponsor Decision.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

